AGE, BLASTS, PERFORMANCE STATUS AND LENALIDOMIDE THERAPY INFLUENCE THE OUTCOME OF MYELODYSPLASTIC SYNDROME WITH ISOLATED DEL(5q): A STUDY OF 58 SOUTH AMERICAN PATIENTS

This study analyzed the overall survival (OS) of patients with Myelodysplastic Syndrome (MDS) with isolated deletion 5q in South America. Age>75 years, ECOG ≥2 and BM blasts>2% at diagnosis are independently associated with worse OS. Lenalidomide treatment is the only factor that improves the OS.Background: Myelodysplastic Syndrome (MDS) with isolated deletion 5q is associated with a low risk to leukemic evolution and long overall survival (OS); it comprises 3-4.5% of MDS cases in Latin America classified according to the WHO 2008.

Source: Clinical Lymphoma, Myeloma and Leukemia - July 25, 2021 Category: Hematology Authors: RS Azevedo, C Belli, L Bassolli, L Ferri, MA Perusini, A Enrico, TDM Pereira, WFS Junior, V Buccheri, RF Pinheiro, SM Magalhaes, S Schuster, JB Castelli, F Traina, V Rocha, EDRP Velloso Source Type: research